Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, The Netherlands.
Arthritis Res Ther. 2010;12(2):R61. doi: 10.1186/ar2974. Epub 2010 Apr 6.
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mainly affects synovial joints. Biologics directed against tumor-necrosis-factor (TNF)-alpha are efficacious in the treatment of RA. However, the role of TNF receptor-1 (TNFR1) in mediating the TNFalpha effects in RA has not been elucidated and conflicting data exist in experimental arthritis models. The objective is to investigate the role of TNFR1 in the synovial lining cells (SLC) and the reticuloendothelial system (RES) during experimental arthritis.
Third generation of adenovirus serotype 5 were either injected locally in the knee joint cavity or systemically by intravenous injection into the retro-orbital venous sinus to specifically target SLC and RES, respectively. Transduction of organs was detected by immunohistochemistry of the eGFP transgene. An adenoviral vector containing a short hairpin (sh) RNA directed against TNFR1 (HpTNFR1) was constructed and functionally evaluated in vitro using a nuclear factor-kappaB (NF-kappaB) reporter assay and in vivo in streptococcal cell wall-induced arthritis (SCW) and collagen-induced arthritis (CIA). Adenoviruses were administered before onset of CIA, and the effect of TNFR1 targeting on the clinical development of arthritis, histology, quantitative polymerase chain reaction (qPCR), cytokine analyses and T-cell assays was evaluated.
Systemic delivery of Ad5.CMV-eGFP predominantly transduced the RES in liver and spleen. Local delivery transduced the synovium and not the RES in liver, spleen and draining lymph nodes. In vitro, HpTNFR1 reduced the TNFR1 mRNA expression by three-fold resulting in a 70% reduction of TNFalpha-induced NF-kappaB activation. Local treatment with HpTNFR1 markedly reduced mRNA and protein levels of interleukin (IL)-1beta and IL-6 in SLC during SCW arthritis and ameliorated CIA. Systemic targeting of TNFR1 in RES of liver and spleen by systemic delivery of Ad5 virus encoding for a small hairpin RNA against TNFR1 markedly ameliorated CIA and simultaneously reduced the mRNA expression of IL-1beta, IL-6 and Saa1 (75%), in the liver and that of Th1/2/17-specific transcription factors T-bet, GATA-3 and RORgammaT in the spleen. Flow cytometry confirmed that HpTNFR1 reduced the numbers of interferon (IFN)gamma (Th1)-, IL-4 (Th2)- and IL-17 (Th17)-producing cells in spleen.
TNFR1-mediated signaling in both synovial lining cells and the reticuloendothelial system independently played a major pro-inflammatory and immunoregulatory role in the development of experimental arthritis.
类风湿关节炎(RA)是一种主要影响滑膜关节的自身免疫性炎症性疾病。针对肿瘤坏死因子(TNF)-α的生物制剂在 RA 的治疗中是有效的。然而,TNF 受体-1(TNFR1)在介导 RA 中 TNFalpha 效应中的作用尚未阐明,并且在实验性关节炎模型中存在相互矛盾的数据。本研究的目的是探讨 TNFR1 在实验性关节炎中滑膜衬里细胞(SLC)和网状内皮系统(RES)中的作用。
第三代腺病毒血清型 5 通过局部注射到膝关节腔或静脉内注射到眶后静脉窦,分别靶向 SLC 和 RES。通过 GFP 转基因的免疫组织化学检测器官的转导。构建了一种针对 TNFR1 的短发夹(sh)RNA 的腺病毒载体(HpTNFR1),并通过核因子-kappaB(NF-kappaB)报告基因测定和链球菌细胞壁诱导关节炎(SCW)和胶原诱导关节炎(CIA)在体内进行了功能评估。在 CIA 发病前给予腺病毒,评估 TNFR1 靶向对关节炎临床发展、组织学、定量聚合酶链反应(qPCR)、细胞因子分析和 T 细胞测定的影响。
Ad5.CMV-eGFP 的全身给药主要转导肝脏和脾脏中的 RES。局部给药则转导滑膜而不转导肝脏、脾脏和引流淋巴结中的 RES。体外,HpTNFR1 将 TNFR1mRNA 表达减少了三倍,导致 TNFalpha 诱导的 NF-kappaB 激活减少了 70%。在 SCW 关节炎期间,局部给予 HpTNFR1 可显著降低 SLC 中白细胞介素(IL)-1β和 IL-6 的 mRNA 和蛋白水平,并改善 CIA。通过全身给予编码针对 TNFR1 的短发夹 RNA 的 Ad5 病毒对肝脏和脾脏中的 RES 进行 TNFR1 全身靶向治疗,可显著改善 CIA,并同时降低肝脏中 IL-1β、IL-6 和 Saa1(75%)的 mRNA 表达,以及脾脏中 Th1/2/17 特异性转录因子 T-bet、GATA-3 和 RORgammaT 的 mRNA 表达。流式细胞术证实 HpTNFR1 减少了脾脏中产生干扰素(IFN)γ(Th1)、IL-4(Th2)和 IL-17(Th17)的细胞数量。
TNFR1 介导的信号在滑膜衬里细胞和网状内皮系统中独立地在实验性关节炎的发展中发挥了主要的促炎和免疫调节作用。